HALO logo
LRMR
Larimar Therapeutics, Inc.

LRMR · Larimar Therapeutics, Inc.

1.98

USD
-0.005 (-0.251%)
16/10/2026 04:15:00 PM
+1
Price change (7D)

Unlock stock Insights

Create a free account to unlock price targets, recommendations, and commentary.

Overview

Market Cap

US$277.37M

PE

N/A

EV/EBITDA

N/A

DIV Yield

N/A

Payout Ratio

N/A

MQV Rating

5Very Weak

As at 16/10/2026 04:15:00 PM

Price Chart

Description

Larimar Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing treatments for patients suffering from complex rare diseases using a novel cell penetrating peptide technology platform. It also engages in the research, development, and commercialization of novel therapeutics for mitochondrial disorders and Friedreich's ataxia. The company was founded in 2005 and is headquartered in Bala Cynwyd, PA.

  • All-Companies
  • All-Consensus
  • Extreme Oversold
  • Extreme Oversold (Realtime)
  • HALO All
  • HALO Balance Sheet
  • HALO Consensus Value
  • HALO Earnings Momentum
  • Hammer Bearish
  • Hammer Bullish
  • Near Support (Realtime)
  • Recent Price upgrade

Key Fundamentals

EPS 3 yr Growth

N/A

EBITDA Margin

N/A

Operating Cashflow

N/A

Free Cash Flow Return

N/A

ROIC

N/A

Interest Coverage

N/A

Quick Ratio

N/A

Performance

52 weeks range

N/A

Trade Value (12mth)

N/A

1 week

%

1 month

%

YTD

%

1 year

%

All time high

N/A

Additional Data

Shares Outstanding (Fully Diluted)

N/A

HALO Sector

Healthcare

Next Company Report Date

N/A

Next Ex Dividend Date

N/A

Next Dividend Pay Date

N/A

Reporting Currency

N/A

Short Sell (% of issue)

lock

Consensus

Lock Icon

Unlock full consensus

Consensus score

Lock Icon/10

Recommendation

Buy

Target price

Lock Icon

Deviation

Lock Icon

Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

Mqv

Very Weak

Garp

Very Weak

Mqv Small

Neutral

Momentum

Price

Very Weak

Earnings

Very Strong

Growth

Earnings

Strong

Dividends

Very Weak

Quality

Capital Efficiency

Very Weak

Balance Sheet

Very Strong

Valuation

Lock Icon

Unlock full dataset

Value

Lock Icon

Consensus

Lock Icon

Yield

Lock Icon

News & Announcements

DateEvent
30 September 26EDG
04 August 26EDG
04 August 26EDG
04 August 26EDG
04 August 26EDG

Key Stakeholders

NameTitle
Deerfield Management Co. LP (Private Equity)Subsidiary
Blue Owl Healthcare Opportunities Advisors LLCSubsidiary
Thomas Edward HamiltonIndividual
Michael CelanoIndividual
Carole S. Ben-MaimonIndividual

See beyond the curve.

One solution for research, investing and model portfolio management.
Start FREE Trial
Want to learn more?Frequently asked questions.
1
What is the current share price of Larimar Therapeutics, Inc. (LRMR:NAS)?
Halo FAQ
The current share price of Larimar Therapeutics, Inc. (LRMR:NAS) is USD$1.98.
2
What is the 52-week high share price for Larimar Therapeutics, Inc. (LRMR:NAS)?
Halo FAQ
The 52-week high share price for Larimar Therapeutics, Inc. (LRMR:NAS) is USD$0.00.
3
What is the 52-week low share price for Larimar Therapeutics, Inc. (LRMR:NAS)?
Halo FAQ
The 52-week low share price for Larimar Therapeutics, Inc. (LRMR:NAS) is USD$0.00.
4
What is the dividend yield for Larimar Therapeutics, Inc. (LRMR:NAS)?
Halo FAQ
Larimar Therapeutics, Inc. (LRMR:NAS) does not pay a dividend.
5
What was Larimar Therapeutics, Inc. (LRMR:NAS) last dividend payment?
Halo FAQ
Larimar Therapeutics, Inc. (LRMR:NAS) does not pay a dividend.
6
What is the franking level for Larimar Therapeutics, Inc. (LRMR:NAS)?
Halo FAQ
Larimar Therapeutics, Inc. (LRMR:NAS) has a franking level of 0.00%.
7
In which sector is Larimar Therapeutics, Inc. (LRMR:NAS) classified?
Halo FAQ
Larimar Therapeutics, Inc. (LRMR:NAS) is classified in the Healthcare.